0 rating

Advances in Systemic Chemotherapy for the Treatment of Neuroendocrine Tumors

Seppo W Langer, MD, PhD

In recent years, the options for treating gastroenteropancreatic neuroendocrine tumors (GEP-NET) have changed. The therapeutic advances within the field of peptide receptor radionuclide therapy, as well as the demonstration of clinically meaningful benefit from treatment with the mammalian target of rapamycin (mTOR) inhibitor everolimus and the receptor tyrosine kinase vascular endothelial growth factor receptor (VEGFR) inhibitor sunitinib, have resulted in new treatment options for patients with advanced disease. The continuous efforts to optimize somatostatin analogues also appear to be beneficial in terms of better symptom control and better tumor control. Moreover, the use of classic cytostatic treatment has also changed. This review seeks to summarize some the recent advances in systemic treatment with chemotherapy in patients with advanced GEP-NET.

Return to top


Our most popular articles